logo
  

Abcam Appoints Sue Harris As Non-Executive Director - Quick Facts

Life science research tools supplier Abcam plc (ABC.L) said it has named Sue Harris as a non-Executive Director on the Abcam board, effective immediately, and would Chair the Audit Committee.

Sue, who's a Chemist by training, has more than 30 years of financial and commercial experience. She began her career at Ford Motor Co. before moving to oil company Amerada Hess. Subsequently, Sue held senior executive roles at Marks & Spencer, across finance and latterly as Head of Corporate Development, and Standard Life where she led the process to float the company on the London Stock Exchange in 2006.

Sue is a Member of the Audit and Assurance Council of the Financial Reporting Council and previously was a Non-Executive Director on the Board of St. James's Place and a Member of the Audit and Remuneration Committee of the British Bankers' Association.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT